These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38069034)

  • 1. FARSB Facilitates Hepatocellular Carcinoma Progression by Activating the mTORC1 Signaling Pathway.
    Wang Y; Wang G; Hu S; Yin C; Zhao P; Zhou X; Shao S; Liu R; Hu W; Liu GL; Ke W; Song Z
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTORC1 Promotes ARID1A Degradation and Oncogenic Chromatin Remodeling in Hepatocellular Carcinoma.
    Zhang S; Zhou YF; Cao J; Burley SK; Wang HY; Zheng XFS
    Cancer Res; 2021 Nov; 81(22):5652-5665. PubMed ID: 34429326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant amino acid signaling promotes growth and metastasis of hepatocellular carcinomas through Rab1A-dependent activation of mTORC1 by Rab1A.
    Xu BH; Li XX; Yang Y; Zhang MY; Rao HL; Wang HY; Zheng XF
    Oncotarget; 2015 Aug; 6(25):20813-28. PubMed ID: 26308575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
    Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
    J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
    Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
    Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-21-5p Inhibits Ferroptosis in Hepatocellular Carcinoma Cells by Regulating the AKT/mTOR Signaling Pathway through MELK.
    Hu Z; Li L; Li M; Zhang X; Zhang Y; Ran J; Li L
    J Immunol Res; 2023; 2023():8929525. PubMed ID: 37008632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR regulates aerobic glycolysis through NEAT1 and nuclear paraspeckle-mediated mechanism in hepatocellular carcinoma.
    Zhang H; Su X; Burley SK; Zheng XFS
    Theranostics; 2022; 12(7):3518-3533. PubMed ID: 35547764
    [No Abstract]   [Full Text] [Related]  

  • 9. Compound heterozygosity for loss-of-function FARSB variants in a patient with classic features of recessive aminoacyl-tRNA synthetase-related disease.
    Antonellis A; Oprescu SN; Griffin LB; Heider A; Amalfitano A; Innis JW
    Hum Mutat; 2018 Jun; 39(6):834-840. PubMed ID: 29573043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations.
    Adebayo Michael AO; Ko S; Tao J; Moghe A; Yang H; Xu M; Russell JO; Pradhan-Sundd T; Liu S; Singh S; Poddar M; Monga JS; Liu P; Oertel M; Ranganathan S; Singhi A; Rebouissou S; Zucman-Rossi J; Ribback S; Calvisi D; Qvartskhava N; Görg B; Häussinger D; Chen X; Monga SP
    Cell Metab; 2019 May; 29(5):1135-1150.e6. PubMed ID: 30713111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. USP10 suppresses tumor progression by inhibiting mTOR activation in hepatocellular carcinoma.
    Lu C; Ning Z; Wang A; Chen D; Liu X; Xia T; Tekcham DS; Wang W; Li T; Liu X; Liu J; Qi H; Luo H; Du J; Ma C; Yan Q; Liu J; Xu G; Piao HL; Tan G
    Cancer Lett; 2018 Nov; 436():139-148. PubMed ID: 30056112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
    Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
    Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TANGO1 interacts with NRTN to promote hepatocellular carcinoma progression by regulating the PI3K/AKT/mTOR signaling pathway.
    Man J; Zhou W; Zuo S; Zhao X; Wang Q; Ma H; Li HY
    Biochem Pharmacol; 2023 Jul; 213():115615. PubMed ID: 37211171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discoidin domain receptor 1 promotes hepatocellular carcinoma progression through modulation of SLC1A5 and the mTORC1 signaling pathway.
    Pan Y; Han M; Zhang X; He Y; Yuan C; Xiong Y; Li X; Zeng C; Lu K; Zhu H; Lu X; Liu Q; Liang H; Liao Z; Ding Z; Zhang Z; Chen X; Zhang W; Zhang B
    Cell Oncol (Dordr); 2022 Feb; 45(1):163-178. PubMed ID: 35089546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.
    Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
    Int J Med Sci; 2021; 18(15):3588-3598. PubMed ID: 34522186
    [No Abstract]   [Full Text] [Related]  

  • 16. FARSB serves as a novel hypomethylated and immune cell infiltration related prognostic biomarker in hepatocellular carcinoma.
    Zhen J; Pan J; Zhou X; Yu Z; Jiang Y; Gong Y; Ding Y; Liu Y; Guo L
    Aging (Albany NY); 2023 Apr; 15(8):2937-2969. PubMed ID: 37074800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of AIM2 expression promotes hepatocarcinoma progression through activation of mTOR-S6K1 pathway.
    Ma X; Guo P; Qiu Y; Mu K; Zhu L; Zhao W; Li T; Han L
    Oncotarget; 2016 Jun; 7(24):36185-36197. PubMed ID: 27167192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOX18 Affects Cell Viability, Migration, Invasiveness, and Apoptosis in Hepatocellular Carcinoma (HCC) Cells by Participating in Epithelial-to-Mesenchymal Transition (EMT) Progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin (mTOR).
    Sun Y; Lei B; Huang Q
    Med Sci Monit; 2019 Aug; 25():6244-6254. PubMed ID: 31427562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of mTORC2 Induces Cell-Cycle Arrest and Enhances the Cytotoxicity of Doxorubicin by Suppressing MDR1 Expression in HCC Cells.
    Chen BW; Chen W; Liang H; Liu H; Liang C; Zhi X; Hu LQ; Yu XZ; Wei T; Ma T; Xue F; Zheng L; Zhao B; Feng XH; Bai XL; Liang TB
    Mol Cancer Ther; 2015 Aug; 14(8):1805-15. PubMed ID: 26026051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
    Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
    Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.